Donny Ramadhan

Donny Ramadhan

Auto-generated profile, based on publicly available information

Donny Ramadhan

Laboratory for Computational Biology, Institute for Protein Research

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
RURamadhita Umitaibatin
Ramadhita Umitaibatin
AHAzza Hanif Harisna
Azza Hanif Harisna
MJMuhammad Miftah Jauhar
Muhammad Miftah Jauhar
PSPutri Hawa Syaifie
Putri Hawa Syaifie
AAAdzani Gaisani Arda
Adzani Gaisani Arda
IAIsa Anshori
Isa Anshori
The coronavirus disease 2019 outbreak has become a huge challenge in the human sector for the past two years. The coronavirus is capable of mutating at a higher rate than other viruses. Thus, an approach for creating an effective vaccine is still needed to induce antibodies against multiple variants with lower side effects. Currently, there is a lack of research on designing a multiepitope of the COVID-19 spike protein for the Indonesian population with comprehensive immunoinformatic analysis. Therefore, this study aimed to design a multiepitope-based vaccine for the Indonesian population using an immunoinformatic approach. This study was conducted using the SARS-CoV-2 spike glycoprotein sequences from Indonesia that were retrieved from the GISAID database. Three SARS-CoV-2 sequences, with IDs of EIJK-61453, UGM0002, and B.1.1.7 were selected. The CD8+ cytotoxic T-cell lymphocyte (CTL) epitope, CD4+ helper T lymphocyte (HTL) epitope, B-cell epitope, and IFN-γ production were predicted. After modeling the vaccines, molecular docking, molecular dynamics, in silico immune simulations, and plasmid vector design were performed. The designed vaccine is antigenic, non-allergenic, non-toxic, capable of inducing IFN-γ with a population reach of 86.29% in Indonesia, and has good stability during molecular dynamics and immune simulation. Hence, this vaccine model is recommended to be investigated for further study.

1 March 2024 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
AAAdzani Gaisani Arda
Adzani Gaisani Arda
PSPutri Hawa Syaifie
Putri Hawa Syaifie
DRDonny Ramadhan
Donny Ramadhan
MJMuhammad Miftah Jauhar
Muhammad Miftah Jauhar
DNDwi Wahyu Nugroho
Dwi Wahyu Nugroho
EMEtik Mardliyati
Etik Mardliyati
Context: Matrix metalloproteinases (MMPs) play a critical role in wound healing, with higher levels seen in chronic wounds, delaying healing. Since ancient times, propolis has been widely used for traditional wound healing. However, there is still limited research on MMP1 and MMP12. Aims: To evaluate new candidates of propolis compounds for targeting MMP1 and MMP12 using in silico studies supported by experimental screening using LC-MS/MS quadrupole-time of flight (QTOF). Methods: Compounds in propolis were screened using LC-MS/MS QTOF. The 3D structure of all compounds in propolis and protein targets was prepared in Autodock and Biovia Discovery Studio. The molecular docking of all compounds in propolis was carried out using Autodock on PyRx 0.9. Drug-likeness and ADMET analysis of selected compounds in propolis with the lowest affinity were observed. Lastly, molecular dynamic simulations of the best compounds in propolis were conducted using the GROMACS 2020 package. Results: Eleven flavonoid and phenolic compounds were identified in propolis using LC-MS/MS QTOF analysis. Molecular docking simulations showed that licoflavone A and pinostrobin exhibited the lowest binding affinity to MMP1 and MMP12, respectively. Molecular dynamic simulations revealed that licoflavone A formed a more stabilized complex with MMP1, while pinostrobin formed a more stabilized complex with MMP12 than the native ligand. Conclusions: This study revealed new candidates for MMP1 and MMP12 inhibitors from propolis compounds that can enhance wound healing. It is hoped that the evidence gathered in this study provides crucial new information in exploring new wound-healing medications.

19 October 2024 in Heliyon
Verified
Journal Article
Open access
Paula Mariana KustiawanPaula Mariana Kustiawan
Paula Mariana Kustiawan
KSKhalish Arsy Al Khairy Siregar
Khalish Arsy Al Khairy Siregar
MJMuhammad Miftah Jauhar
Muhammad Miftah Jauhar
DRDonny Ramadhan
Donny Ramadhan
EMEtik Mardliyati
Etik Mardliyati
PSPutri Hawa Syaifie
Putri Hawa Syaifie
Hepatocellular Carcinoma (HCC) is commonly treated with surgery, liver transplantation, and chemotherapy, but recurrence and metastasis remain challenges. Natural complementary therapies like propolis, known for its hepatoprotective properties, are gaining interest due to limited efficacy and toxicity of conventional chemotherapy. This study aims to identify core targets for HCC, assess the therapeutic potential of East Kalimantan propolis (EKP) from stingless bees, and analyze the molecular interactions. EKP compounds were analyzed using target prediction tools related to HCC, alongside clinical data from the Gene Expression Omnibus (GEO) database, to identify overlapping genes with clinical relevance. The selected genes were then subjected to protein-protein interaction (PPI), GO and KEGG enrichment, immunohistochemical comparison and survival analysis to identify potential core targets and related pathways for HCC therapy. Furthermore, molecular docking and dynamics were conducted to verify the molecular interactions and stability of EKP compounds with targets. 108 genes have been selected as HCC potential targets, which mostly associated with MicroRNAs in cancer, chemical carcinogenesis, and viral carcinogenesis pathways. These targets were obtained by overlapping genes from GEO clinical databases and target predictors. PPI network analysis revealed 4 main targets of propolis in HCC. Furthermore, differential expression genes, survival analysis, and Immunohistochemical analysis from databases suggested that AKR1C3 and MAPK1 promote HCC progression and shorten survival rate of HCC patients. Molecular docking and dynamic studies confirmed strong binding affinity and stability of Baicalein, Chrysin, Quercetin, and Myricetin with receptor targets within simulation time. This study provides insight into the mechanism of action of EKP on HCC and identifies AKR1C3 and MAPK1 as candidate target treatments for future drug development.

25 October 2023 in Archives of Physiology and Biochemistry
Verified
Journal Article
Closed access
SNSri Ningsih
Sri Ningsih
SKSiska Andrina Kusumastuti
Siska Andrina Kusumastuti
NNNuralih Nuralih
Nuralih Nuralih
AFAdam Arditya Fajriawan
Adam Arditya Fajriawan
DPDevi Permatasari
Devi Permatasari
ASAgus Supriyono
Agus Supriyono
Hyperglycaemia is one condition related to inflammation leading to insulin signalling impairment. This study was conducted to investigate the insulin sensitivity improvement of Sambiloto (Andrographis paniculata (Burm. f.)) Nees extract in insulin resistance-induced HepG2 (IR-HepG2) cells by stimulating insulin sensitivities and inhibiting inflammatory response. Sambiloto extract at 2 µg/mL revealed glucose uptake stimulation and up-regulating GLUT-2 and IRS-1 gene expression, and inhibited pro-inflammatory cytokine IL-6 gene expression in IR-HepG2 cells. Phytochemical analysis showed that the total phenolic level and andrografolide content of Sambiloto extract were 2.91 ± 0.04% and 1.95%, respectively. This result indicated that Sambiloto extract ameliorated insulin resistance in high glucose-induced IR-HepG2 cells via modulating the IRS-1/GLUT-2 pathway due to IL-6 inhibition. These findings suggested that Sambiloto extract had potency as an anti-inflammatory and insulin-resistance improvement in IR-HepG2 cells.

7 September 2022 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
RKRegina Katelia
Regina Katelia
MJMuhammad Miftah Jauhar
Muhammad Miftah Jauhar
PSPutri Hawa Syaifie
Putri Hawa Syaifie
DNDwi Wahyu Nugroho
Dwi Wahyu Nugroho
DRDonny Ramadhan
Donny Ramadhan
IAIsa Anshori
Isa Anshori
Objective: Hypertension is the leading contributor to all-cause death and disability worldwide. One of the most well-known first-line antihypertensive drugs is chlorthalidone which treats hypertension through carbonic anhydrase (CA) II inhibition. However, due to the high number of cases of hypertension, a more potent medication is still needed. Xanthone is a potential candidate for the compound group for its potency in inhibiting CA II. Therefore, this research aims to evaluate around 500 xanthones’ potency as a better oral antihypertensive drug than chlorthalidone. Methods: 507 xanthones were analyzed for their potency using in silico method. Xanthone’s structures were retrieved from the PubChem website or built using Avogadro software, while the CA II receptor was retrieved from The RCSB website. Then molecular docking, ADME evaluation, and toxicity test were evaluated from selected ligands. Finally, a molecular dynamics simulation was conducted to evaluate the stability of the potential ligand as the inhibitor of CA II protein. Results: This research found that globulixanthone c is considered to be a better CA II inhibitor compared to chlorthalidone. It is due to its lower binding affinity compared to chlorthalidone and its stable binding to CA II’s important inhibition sites with low fluctuation. It also has the potential to be consumed orally because it fulfills all of Lipinski's rule of five standards and its toxicity is on the moderate level. Conclusion: Globulixanthone c, a type of prenylated xanthones group, showed the best potential activity as the inhibitor of CA II protein to treat hypertension among other xanthones.

11 September 2025 in ACS Omega
Verified
Journal Article
Open access
DRDonny Ramadhan
Donny Ramadhan
RWReiko Watanabe
Reiko Watanabe
KMKenji Mizuguchi
Kenji Mizuguchi
Natural products exhibit diverse and typically nonflat structures, which could be essential in drug-target interactions. Given limited bioactivity data for natural products in public databases, multitask learning (MTL) offers a promising strategy to improve quantitative structure-activity relationship (QSAR)-based predictions. This study optimized MTL with evolutionary relatedness metrics of proteins to enhance the prediction of natural product bioactivity, particularly when data are scarce, and identified conditions under which MTL is most effective. A curated data set of predicted natural products with bioactivity against enzymes from ChEMBL was constructed using binary classification filtering. Single-task learning (STL) served as the baseline, feature-based MTL (FBMTL) was applied across all proteins within each protein group, and instance-based MTL (IBMTL), a variant of FBMTL, incorporated evolutionary relatedness metrics. IBMTL outperformed STL and FBMTL across most protein groups, suggesting that evolutionary relatedness improves performance. Significant improvements were observed in the kinase and cytochrome P450 protein groups, whose proteins are classified at more specific levels of ChEMBL's 6-level hierarchical protein classification. In the kinase group, IBMTL performed best at the target parent level, highlighting a trade-off between relatedness and data set size. This study demonstrates the potential of MTL in natural product-based drug discovery by leveraging evolutionary relatedness despite limited data availability.